世界卫生组织支持的PARTNERS临床试验已在刚果民主共和国开始招募患者，用于评估两种抗病毒疗法对Bundibugyo病毒病（BVD）的治疗效果1。该试验将测试单克隆抗体MBP134和瑞德西韦两种治疗方案1，旨在为这一致命疾病寻找首个有效的获批治疗方案1。
刚果民主共和国目前已有超过1400人确诊感染Bundibugyo病毒病，近440人死亡，近210人康复1。试验由WHO、刚果民主共和国国家生物医学研究所、比利时热带医学研究所、牛津大学和Africa CDC等多个国际机构协调1。参与试验的患者将获得至少28天的持续支持和随访1，支持性护理包括口服或静脉输液、电解质补充、氧气支持、血压管理和疼痛控制1。试验面向任何年龄的确诊患者开放1。
WHO总干事Tedros Adhanom Ghebreyesus表示："即使没有获批的治疗方案，人们也在从这种疾病中康复，但当然，有了安全有效的治疗药物，我们可以拯救更多生命"1。
Patient enrolment has begun in the PARTNERS clinical trial, a WHO-supported study designed to evaluate the effectiveness of two antiviral therapies against Bundibugyo virus disease (BVD) in the Democratic Republic of the Congo.1 The trial will assess monoclonal antibody MBP134 and remdesivir as potential treatments for the deadly infection.1 This marks a significant step toward identifying the first approved therapeutic options for a disease that has claimed nearly 440 lives among over 1,400 confirmed cases in the region, with approximately 210 patients having recovered.1
The PARTNERS trial—which stands for Platform Adaptive Randomised Trial for New and Repurposed Filovirus Treatments—is coordinated by multiple international institutions, including the Democratic Republic of the Congo's National Institute of Biomedical Research (INRB), the Institute of Tropical Medicine in Belgium, the University of Oxford, and the Africa CDC.1 Patients of any age diagnosed with BVD will be eligible for enrolment and will receive at least 28 days of continuous support and follow-up care, which includes oral or intravenous fluids, electrolyte supplementation, oxygen support, blood pressure management, and pain control.1 According to WHO Director-General Tedros Adhanom Ghebreyesus, "Even without approved therapeutics, people are recovering from this disease, but of course, we could save many more lives with safe and effective therapeutics in our toolkit."1
评论
还没有评论，欢迎留下第一条。